Øystein Åmellem, PhD

Placeholder Person Graphic
Thermo Fisher Scientific
Oystein Amellem, PhD, has held leadership positions in research and development, product management, and business for over 21 years at Thermo Fisher Scientific. Oystein is responsible for development and commercialization of products and services, including the cell therapy market. His training is in the field of molecular cell biology and he received his PhD from the University of Oslo. Oystein’s academic career focused on the study of physiological and molecular mechanisms of tumor cell growth and involved investigating the method of actions for a novel group of anticancer compounds developed by Norsk Hydro.

Related Articles

Comparison between autologous therapies and allogeneic therapies
Features
Supporting Scalable Cell Therapy Using Allogeneic Workflows

Historically, cell therapies are used to treat patients with cancer after relapse from other approved treatment modalities, or if no approved treatment is available. However, the introduction of allogeneic cell therapies has created exciting opportunities to broaden access to cell-based treatments. With advancements in manufacturing, developers are becoming increasingly interested in...